Restoring Vision Through the Science of Renewal
Inspired by the Wnt pathway—an innate pathway for renewal and repair—we develop multi-target antibody therapeutics to improve and restore sight.
About Surrozen
Surrozen was founded by scientific leaders who uncovered the fundamental biology of Wnt (pronounced “wint”) signaling, a key pathway that orchestrates tissue repair and regeneration. Building on this legacy, we developed a proprietary antibody-engineering platform to discover multifunctional antibodies that precisely modulate Wnt signaling and other key drivers of disease pathology”. Our current drug candidates target ophthalmic diseases with high unmet needs and have best-in-disease potential.
Our Science
Our scientific founders made landmark discoveries that defined the role and function of Wnt signaling as one of the central regulators of stem cell renewal and cell fate, as well as tissue structure, function, and repair. Building on this foundation, Surrozen scientists uncovered fundamental insights into how to precisely modulate the Wnt pathway—a key signaling cascade of tissue repair and vascular integrity. These advances led to the development of our proprietary platform that creates multifunctional antibodies capable of Wnt pathway modulation while also addressing other pathways implicated in of ophthalmic disease to create best-in-class therapies.
Our Pipeline
Built on a foundation of Wnt pathway biology, our growing portfolio of antibody therapeutics focuses on ophthalmic diseases with significant unmet medical need.